Conference abstract · 5 Sep 2011
Conference abstractPublished 5 Sep 2011
Vaccine testing using humanized mice
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The ability to assess human immune responses for the development of new vaccines is critical because responses shown in animal models frequently do not reliably translate to humans. We have developed a humanized mouse that utilizes the immunodefi cient Nod scid IL-2Rc-/- mouse background engraft ed with human peripheral blood lymphocytes (PBLs) and supplemented with human BLyS (B lymphocyte stimulator, BAFF) to use for vaccine testing. Both human B and T lymphocytes readily engraft in this mouse and form follicular-like structures in the spleen. We have used model antigens and have shown that both T-cell dependent (peptide plus protein adjuvant) and T-cell independent (Pneumovax23 polysaccharides) antigens generate antibody responses. Recently, we have been testing virus-like particles (VLPs) as a method of presenting antigens in a more native form to the humanized mouse immune system. In collaboration with other investigators, we have engineered VLPs on a Newcastle Disease Virus background that contain surface antigens for Respiratory Synctial Virus (RSV) or HIV. Humanized mice, immunized with these VLPs, have mounted serum antibody responses by day 14 post-priming. Secondary immunization results in even higher antibody titers. Upon takedown of the mice at 21-28 days post-immunization, we can readily detect antigen specifi c antibody secreting cells in the spleen and bone marrow by Elispot analysis. Because PBLs are used to reconstitute these mice, the responses of multiple donors can be used to assess the immunogenicity of new vaccine formulations providing a good basis for clinical testing.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Jul 2015
Key steps in moving a vaccine from proof of concept in mice to human clinical trials
Opinion · 28 Jun 2023
Vaccine Development: Pre-Market Testing and Evaluation of Safety in Humans and Animals
Review article · 30 Jun 2021
Current Regulatory and Pharmacopoeial Status of Mycoplasma Testing in Concern with Vaccines Safety for Human Use
Research article · 30 Aug 2022
Acute Toxicity Test of Standardized Ethanol Extract of Gandasuli Rhizome (Hedycium coronarium) and histopathology of organs in white mice male (Mus muculus)
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
How is really working adaptive immune system in mammals? A novel conception and reverse pathway theory, which will bring novel multibillion super-antibody (sab) technology for curing of all of infectious diseases and cancer!
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Madelyn R. Schmidt”

